Tarsus Pharmaceuticals Q3 net loss widens to $668.33 million
TARS•Tarsus Pharmaceuticals’ third-quarter 2026 net loss widened year over year to $668.3 million, while net product sales rose about 64% to $194.6 million. Acquired in-process research and development expenses totaled $632.2 million.
1. Quarterly results
Tarsus Pharmaceuticals reported a third-quarter 2026 net loss of $668.3 million, compared with a smaller loss a year earlier. Net product sales increased about 64% year over year to $194.6 million, driven by higher volume and improved gross-to-net discounts; acquired in-process research and development expenses were $632.2 million, related to the iRenix Medical and Alkeus Pharmaceuticals acquisitions.
2. Trial results expected
The company expects topline results from Phase 2 trials of TP-04 for ocular rosacea and TP-05 for Lyme disease prevention in the first half of 2027.
